Key takeaways
Tirzepatide (Zepbound) and semaglutide (Rybelsus) are both medications used to help manage weight and treat conditions related to obesity, and they work in a similar way. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, while semaglutide is solely a GLP-1 receptor agonist. Both medications can help with weight loss, but only tirzepatide is FDA-approved for weight management and sleep apnea, whereas semaglutide is approved for Type 2 diabetes. Tirzepatide is administered as a weekly injection, while semaglutide is taken orally once a day. Common side effects for both include nausea and diarrhea, but tirzepatide may also cause injection site reactions. Both medications can lead to low blood sugar if combined with certain diabetes medications. Neither medication is available in a generic form. Additionally, both tirzepatide and semaglutide carry a risk of thyroid cancer, and you should avoid them if you have a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2).
